Infinity Pharmaceuticals Stock Price To Earning
Infinity Pharmaceuticals fundamentals help investors to digest information that contributes to Infinity Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Infinity Stock. The fundamental analysis module provides a way to measure Infinity Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infinity Pharmaceuticals stock.
Infinity |
Infinity Pharmaceuticals Company Price To Earning Analysis
Infinity Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Infinity Pharmaceuticals Price To Earning | (1.63) X |
Most of Infinity Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Infinity Pharmaceuticals has a Price To Earning of -1.63 times. This is 106.31% lower than that of the Biotechnology sector and 133.06% lower than that of the Health Care industry. The price to earning for all United States stocks is 105.68% higher than that of the company.
Infinity Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infinity Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infinity Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Infinity Pharmaceuticals by comparing valuation metrics of similar companies.Infinity Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Infinity Fundamentals
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X | |||
| Price To Sales | 19.29 X | |||
| Revenue | 2.59 M | |||
| Gross Profit | (31.38 M) | |||
| EBITDA | (44.84 M) | |||
| Net Income | (44.37 M) | |||
| Cash And Equivalents | 56.58 M | |||
| Cash Per Share | 0.63 X | |||
| Total Debt | 917 K | |||
| Debt To Equity | 0.13 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | (0.41) X | |||
| Cash Flow From Operations | (42.43 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.45) X | |||
| Price To Earnings To Growth | (0.05) X | |||
| Target Price | 0.3 | |||
| Number Of Employees | 30 | |||
| Beta | 1.38 | |||
| Market Capitalization | 2.63 M | |||
| Total Asset | 42.15 M | |||
| Retained Earnings | (855.95 M) | |||
| Working Capital | 26.67 M | |||
| Current Asset | 254.7 M | |||
| Current Liabilities | 70.06 M | |||
| Z Score | -29.4 | |||
| Net Asset | 42.15 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |